John W. Kozarich – Chairman

John W. Kozarich, PhD, has served as a director since March, 2003. Dr. Kozarich is Chairman and President, and a Director of ActivX Biosciences. From 1992 to 2001, Dr. Kozarich was vice president at Merck Research Laboratories, where he was responsible for a number of research programs. Dr. Kozarich is also a biotechnology professor at the Scripps Research Institute, and previously held faculty positions at the University of Maryland and Yale University School of Medicine. Dr. Kozarich earned his BS in chemistry from Boston College, his PhD in biological chemistry from the Massachusetts Institute of Technology, and was an NIH Postdoctoral Fellow at Harvard.

Jason Aryeh

Jason Aryeh has served as a Director since October, 2006. Mr. Aryeh is Founder and General Partner of JALAA Equities, LLP, a private hedge fund focused on the Biotechnology and Specialty Pharmaceutical sector. Mr. Aryeh actively serves as both a Special Advisor to the Cystic Fibrosis Foundation (CFF) for Drug Discovery, and as Honorary Chairman of the New Mexico Chapter of the CFF.   Mr. Aryeh received his AB with honors in economics from Colgate University.

Todd C. Davis

Todd C. Davis is a Managing Director of Cowen and a Principal and Founder of Cowen Healthcare Royalty Partners (CHRP). Previously, Mr. Davis was a Partner at Paul Capital Partners, where he oversaw investments for the Paul Royalty Funds. Prior to that, Mr. Davis was a Partner at Apax Partners. Mr. Davis has extensive healthcare operating experience, having worked in business development and general management at Elan Pharmaceuticals, and in sales and marketing at Abbott Laboratories. He is a former U.S. naval officer and holds a BS in mathematics from the U.S. Naval Academy, and an MBA from Harvard Business School.

Elizabeth M. Greetham

Elizabeth M. Greetham is Chief Executive Officer and President of ACCL Financial Consultants Ltd. From 1998 until 2004, Ms. Greetham served as a Director of DrugAbuse Sciences, Inc.; as Chief Executive Officer from August, 2000, until 2004; and as Chief Financial Officer and Senior Vice President, Business Development, from April, 1999 to August, 2000. Prior to joining DrugAbuse Sciences, Inc., Ms. Greetham was a Portfolio Manager with Weiss, Peck & Greer, an institutional investment management firm. She was previously a consultant to F. Eberstadt & Co. Ms. Greetham earned a MA (Honors) degree in economics from the University of Edinburgh, Scotland, in 1971.

John L. Higgins

John L. Higgins is President, Chief Executive Officer and a member of the Board of Directors of Ligand Pharmaceuticals Inc. Prior to joining Ligand, Mr. Higgins served as Chief Financial Officer and Executive Vice President, Finance and Administration and Corporate Development, of Connetics Corporation, a specialty pharmaceutical company acquired by Stiefel Laboratories in December 2006. Before joining Connetics, he was a member of the executive management team at BioCryst Pharmaceuticals. Currently, he serves as Director on the Boards of Comentis and BioCryst where he is also Chairperson of its Audit Committee. Prior to BioCryst, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins serves as a director of numerous public and private companies. He graduated Magna Cum Laude from Colgate University with an AB in economics.

David M. Knott

David M. Knott is Chief Investment Manager of Knott Partners Management and Dorset Management. Mr. Knott has more than three decades of experience in investing. He began his career at Donaldson, Lufkin & Jenrette, where he became a Vice President in their retail/small institution division.  He left in 1983 to join Mandrakos Associates as a General Partner and Analyst with responsibility for the firm’s investments in the energy and financial services industries.  Mr. Knott was also in charge of most of the firm’s short selling activities.  In late January of 1987, he founded Knott Partners.  Mr. Knott has a BA from the University of Pennsylvania, and an MBA from the Wharton School. 

Jeffrey R. Perry

Jeffrey R. Perry has served as a director since December, 2005. Mr. Perry is Senior Advisor of Third Point LLC. From September, 2003, to January, 2005, Mr. Perry was a partner at Kynikos Associates, Ltd. From 2001 to 2003, Mr. Perry served as senior portfolio manager at SAC Capital Advisors. From 1993 to 2001, he was a general partner and co-Director of Research at Zweig-DiMenna Associates, a large New York-based hedge fund. He graduated Magna Cum Laude from Georgetown University with a BA in American studies.